How is COVID-19 Situation Affecting Dermatology Drugs Market?

 According to the World Health Organization (WHO), around 900 million people are affected by skin disorders worldwide, at any point in time. The organization also states that skin diseases are among the most common health ailments in the world. Warts, pyoderma, acne, scabies, and eczema are some of the most prevalent skin disorders across the globe. Furthermore, acne and freckles affect most of the U.S. population. According to the National Eczema Association, around 31.6 million people in the U.S. were affected by at least one form of eczema in 2019.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/dermatology-drug-market/report-sample

Due to an escalation in the cases of skin problems, the healthcare system has come up with an array of drugs, which include Humira, Otezla, Enbrel, Neoral, Cubicin, Canesten, Dupixent, Valtrex, Remicade, Stelara, Cosentyx, Taltz, Zyvox, Protopic, and Eucrisa. Of these, dermatologists across the world have begun to prefer Eucrisa over other drugs due to its minimal side-effects. As a result, the drug is being extensively used for the treatment of mild-to-moderate atopic dermatitis in adults and children.

Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dermatology-drug-market

These drugs are widely used in hospitals due to the increasing prevalence of skin diseases. The growing cases of skin cancer and rising patient footfall at hospitals will further augment the adoption of dermatology drugs in these healthcare facilities. The increasing pollution and growing rate of ozone layer depletion are expected to intensify the global effect of skin cancer. Furthermore, cosmetic centers are also projected to prescribe high volumes of these drugs due to the availability of beauty services at a reduced cost here, rising focus of people regarding their appearance, and amplifying number of such centers.

With the increasing cases of skin diseases, players in the dermatology drugs market are focused on developing new and better drugs that are swiftly getting approvals from regulatory agencies. For example, Sanofi S.A. received the approval for Dupixent (dupilumab) from the United States Food and Drug Administration (USFDA) in May 2020. This product is used to treat moderate-to-severe atopic dermatitis. Likewise, Bausch Health Companies Inc. and its dermatological branch, Ortho Dermatologics, received the approval for JUBLIA (efinaconazole) topical solution in April 2020, for onychomycosis.

Thus, the spurring cases of skin diseases across the globe are fueling the demand for dermatology drugs.


Comments

Post a Comment

Popular posts from this blog

Huge Growth Expected in Dermacosmetics Market in Future

Image
 The cosmetic industry, while mostly misunderstood as dealing with just the aesthetic appearance, has been undergoing technological advancements and moved beyond face creams and face powders since a long time now. Other than this, the prevalence of skin diseases is also rising across the globe and it has been shown by the Global Burden of Disease project that skin diseases are the 4th leading cause of nonfatal disease burden globally. Moreover, understanding the impact of skin diseases is important as in some cases skin conditions often represent a more severe systemic illness, such as human immunodeficiency virus and neglected tropical diseases.  Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/dermacosmetics-market/report-sample Attributed to these reasons, the development of dermacosmetics has been made possible. These products are crucial now in the branch of dermatology as they combine cosmetics and scientific techniques for the management of a
Read more

Increasing Occurrence of Spinal Cord Injuries Powering Sales of Exoskeletons

Image
The growing prevalence of stroke and spinal cord injuries (SCIs) is fueling the surge in the demand for exoskeletons in several healthcare settings such as rehabilitation centers across the world. In the healthcare industry, exoskeletons are used for helping paralyzed patients walk. For example, as per the National Spinal Cord Injury Statistical Center (NSCISC), in the U.S., there are around 54 cases of SCIs per one million people, or nearly 17,730 new SCI cases are reported every year. Furthermore, in the U.S., the average number of people suffering from spinal cord injuries is 291,000, with various individual estimates falling in the range of 249,000–363,000. The surging geriatric population in several countries is also fueling the demand for exoskeletons. As per the World Population Ageing 2019 report published by the UN, the total number of people in the age bracket- 65 years or above across the world was 703 million in 2019. Moreover, the public awareness about exoskeletons and th
Read more

Why is Population Health Management Market Expected to Boom in North America in Future?

Image
 The soaring global geriatric population, which is expected to reach at least 1.5 billion by 2050, according to the World Health Organization (WHO), is a key factor responsible for the rise in the demand for population health management (PHM). Elderly people require extensive care as they are more susceptible to diseases, especially chronic diseases, such as cancer and cardiovascular ailments, owing to their low immunity levels and high recovery periods. This causes a huge increase in the demand for better prevention, diagnosis, and treatment processes. In addition to this, older people also have a greater requirement for personalized medicine, because of their increased susceptibility to drug allergy, thereby boosting the demand for population health management. Receive Sample Copy of this Report:  https://www.psmarketresearch.com/market-analysis/population-health-management-market/report-sample The other important factors bolstering the demand for PHM are the increasing healthcar
Read more